Mylan Inc. (NYSE:MYL) recently announced that its UK and Italian subsidiaries have launched its generic version of Roche Holding’s (RHHBY) osteoporosis drug, Bonviva (ibandronic acid), 150 mg. Bonviva is a coated tablet with a once-monthly recommended dosing.
According to IMS Health, Bonviva generated revenues of approximately €8.5 million and €27 million in the UK and Italy respectively, for the 12 months ending March 2012. We note that Mylan derives 23.8% of its generic revenues from the … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards